Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Visit NurExone Biologic Inc.

NurExone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.

Stock Quote Today & Recent News NurExone Biologic Inc V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Our first product ExoPTEN for acute spinal cord injury has been granted Orphan Drug Designation by the FDA.

Dr. Lior Shaltiel

Current News (TSXV:NRX)

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

GlobeNewswire 5 days ago

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

GlobeNewswire 10 days ago

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

GlobeNewswire April 2, 2024

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

GlobeNewswire March 27, 2024

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

GlobeNewswire March 22, 2024

NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

GlobeNewswire March 15, 2024
View More News ››

We are developing a unique and futuristic drug delivery system—exosomes deliver therapeutic cargo to tissues and organs, promoting a healing environment for neuroregeneration.

Dr. Lior Shaltiel

Opinion & Analysis (TSXV:NRX)

ExoTherapy offers hope for treating acute spinal cord injuries

Brieanna McCutcheon  September 19, 2023
View More Opinion ››

Bullboard Posts (TSXV:NRX)

NurExone Unlocks Several Milestones Since March 2024

NurExone Unlocks Several Milestones Since March 2024 (TSXV: NRX, FSE: J90, NRX.V) ...
Mathew177 - 11 days ago

This one is a thin trader and no buyer interest

did not hold the 60 cent level ....so likely down she goes.....no news to move it up and establishing a home base in Israel is probably...
88guy88 - April 16, 2024

Price is below the 20 and 50 day average of 70 cents

the 200 day average support is at 38 cents......appears to be bouncing of the 60 cent base but if it falls below that 60....look out...
88guy88 - April 12, 2024

The Rise of NurExone Biologic Inc. in Biopharma (TSXV: NRX)

The Rise of NurExone Biologic Inc. in Biopharma (TSXV: NRX, FSE: J90, NRX.V) https://10xalerts.com/the-rise-of-nurexone-biologic-inc...
Mathew177 - March 20, 2024

Price heading toward mid 50 and 200 day average

the 50 day is 57 where it is today and the 200 day average is 34.....so the middle is around 45 cents decent high risk buy at 45 cents...
88guy88 - March 20, 2024

Why would they set up R&D facility in a war zone!!

...
88guy88 - March 20, 2024
View more Bullboard ››

Connect with V.NRX

Visit Facebook Visit X Visit Linked In Visit Youtube

PRESENTATION TECHNOLOGY - EXOSOMES TECHNOLOGY - EXOTHERAPY MANAGEMENT ANALYST REPORT LEARN ABOUT ODD

Investor Presentation

View the Presentation

Investment Opportunity

NurExone operates according to two business lines – Development of a first exosome-based therapy for acute Spinal Cord Injuries (SCI).

In parallel, the company is monetizing its proprietary ExoTherapy platform through licensing to the global biopharmaceutical industry to deliver therapies for other diseases and indications.

The company’s first product, ExoPTEN, for acute spinal cord injury, has been granted Orphan Drug Designation by the FDA.

Why NurExone??

The Ultimate Drug Delivery System

The Beginning of NurExone

Facebook

Contact Us

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu